Migraine:


A migraine is a common type of
headache that may occur with
symptoms such as nausea, vomiting,
or sensitivity to light. In many people, a
throbbing pain is felt only on one side
of the head.

Some people who get migraines have
warning symptoms, called an aura,
before the actual headache begins. An
aura is a group of symptoms, usually
vision disturbances, that serve as a
warning sign that a bad headache is
coming. Most people, however, do not
have such warning signs.


SUMATRIPAN  SELF-INJECTED  IS
HELPING MIGRAINE SUFFERERS IN
12 MINUTES
A San Diego company called Zogenix
is enjoying strong sales of its product,
the needle-less migraine headache
treatment injector, Sumavel DosePro.
The device uses compressed nitrogen
gas to shoot a thin stream of the
medication sumatriptan into the skin,
helping migraine sufferers in as little as
12 minutes.
Sumatripan is now a generic
medication.
In July 2009, the United States FDA
approved Sumavel DosePro  from
Zogenix Inc., Emeryville and San
Diego, California, USA. This is a
unique pre-filled, single-use delivery
system for 6 mg subcutaneous
sumatriptan. It has no needle, and
uses gas pressure as a power source.
The drug is delivered in less than 100
msec. Sumavel DosePro is about the
size of a white board marker or fat felt-
tipped pen, and became available for
prescription in the USA in early 2010; a
corresponding product application has
been filed in Europe.



BOTOX HAS BEEN APPROVED FOR
TREATMENT OF MIGRAINE BY THE
FDA AND LICENSED IN THE UK
BOTOX is a prescription-only medical
product that contains tiny amounts of
highly purified botulinum toxin protein
refined from the bacterium, Clostridium
botulinum.

At the end of a 28 day baseline period,
patients were randomised to receive
either 155 - 195 units of BOTOX
administered as 31 injections (155
units) into 7 specific head and neck
muscle with an additional up to 8
injections (up to 40 units) into 3 of
these muscles that could be
administered in a 'follow the pain'
strategy, or placebo. Patients received
2 injection cycles in a 24 week double-
blind phase and then 3 injection cycles
in a 32 week open label phase.

Patients treated with BOTOX
experienced significantly fewer
headache days compared to those
patients treated with placebo (47.1% of
BOTOX treated patients compared to
35.1% of placebo treated patients
achieved ≥50% reduction from
baseline in the number of headache
days at the week 24 primary timepoint,
p<0.001)

- Following the open label phase of the
trial (week 56), nearly 70% of BOTOX
treated patients experienced ≥50%
reduction from baseline in migraine
days.

Botox is made by California based
Allergan. The FDA is  approved Botox
for migraine in October  2010.


REPAIRING  A HOLE IN THE HEART
TO TREAT MIGRAINE PROBLEM
A study is under way  to patch small
holes in hearts in order to fix migraine
headaches. The procedure is called
Patent Foramen Ovale and utilizes a
catheter to guide a small sheath of
fabric,  to cover both sides of the hole.



CALCITONIN GENE-RELATED
PEPTIDES TESTED FOR MIGRAINE
Trial  to investigate Calcitonin Gene-
related Peptide Levels in Chronic
Migraine.
This double-blind study will evaluate
reduction in number of headache days
following treatment with Botox versus
placebo. Additionally, CGRP levels in
saliva will be correlated with a
reduction in headache attacks.
Trial no:  NCT01071096




OTHER DEVELOPMENTS:

Implanted electrical stimulator;

Occipital Nerve Stimulator;

TMS transcranial magnetic stimulation;

Levadex by Map Pharma;

Zomig Rapimelt by Astrazeneca;